[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” border_style=”solid” flex_column_spacing=”0px” type=”legacy”][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ align_self=”auto” content_layout=”column” align_content=”flex-start” content_wrap=”wrap” spacing=”” center_content=”no” link=”” target=”_self” min_height=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” sticky_display=”normal,sticky” class=”” id=”” type_medium=”” type_small=”” order_medium=”0″ order_small=”0″ dimension_spacing_medium=”” dimension_spacing_small=”” dimension_margin_medium=”” dimension_margin_small=”” padding_medium=”” padding_small=”” hover_type=”none” border_sizes=”” border_color=”” border_style=”solid” box_shadow=”no” box_shadow_blur=”0″ box_shadow_spread=”0″ box_shadow_color=”” box_shadow_style=”” gradient_start_color=”” gradient_end_color=”” gradient_start_position=”0″ gradient_end_position=”100″ gradient_type=”linear” radial_direction=”center center” linear_angle=”180″ background_color=”” background_image=”” background_image_id=”” background_position=”left top” background_repeat=”no-repeat” background_blend_mode=”none” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=”” filter_hue=”0″ filter_saturation=”100″ filter_brightness=”100″ filter_contrast=”100″ filter_invert=”0″ filter_sepia=”0″ filter_opacity=”100″ filter_blur=”0″ filter_hue_hover=”0″ filter_saturation_hover=”100″ filter_brightness_hover=”100″ filter_contrast_hover=”100″ filter_invert_hover=”0″ filter_sepia_hover=”0″ filter_opacity_hover=”100″ filter_blur_hover=”0″ element_content=”” first=”true” last=”true” border_position=”all” type=”1_1″][fusion_content_boxes layout=”timeline-vertical” columns=”1″ heading_size=”2″ iconspin=”no” image_max_width=”” icon_align=”left” animation_direction=”left” animation_speed=”0.3″ hide_on_mobile=”small-visibility,medium-visibility,large-visibility” link_type=”text”][fusion_content_box title=”Tebentafusp-tebn (Kimmtrak, Immunocore Limited)” backgroundcolor=”” icon=”fa-arrow-alt-circle-right fas” iconflip=”” iconrotate=”” iconspin=”” iconcolor=”” circlecolor=”” circlebordercolor=”” image=”” image_id=”” image_max_width=”80″ link=”” linktext=”Leia mais” animation_type=”” animation_direction=”left” animation_speed=”0.3″ link_target=”_blank”]
- Acoplador de células T CD3 dirigido por peptídeo gp100 biespecífico
- Pacientes adultos HLA-A*02:01-positivos com doença irressecável ou melanoma uveal metastático
[/fusion_content_box][fusion_content_box title=” Pembrolizumab (Keytruda, Merck)” backgroundcolor=”” icon=”fa-arrow-alt-circle-right fas” iconflip=”” iconrotate=”” iconspin=”” iconcolor=”” circlecolor=”” circlebordercolor=”” image=”” image_id=”” image_max_width=”” link=”” linktext=”Read More” animation_type=”” animation_direction=”left” animation_speed=”0.3″]
- Tratamento adjuvante de pacientes adultos e pediátricos (≥12 anos de idade) com melanoma em estágio IIB ou IIC após ressecção completa.
[/fusion_content_box][fusion_content_box title=”Rituximabe (Rituxan, Genentech, Inc.)” backgroundcolor=”” icon=”fa-arrow-alt-circle-right fas” iconflip=”” iconrotate=”” iconspin=”” iconcolor=”” circlecolor=”” circlebordersize=”” circlebordercolor=”” outercirclebordersize=”” outercirclebordercolor=”” image=”” image_id=”” image_max_width=”” link=”” linktext=”” link_target=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=””]
- Rituximabe (Rituxan, Genentech, Inc.) em combinação com quimioterapia para pacientes pediátricos (≥6 meses a <18 anos) com estágio avançado não tratado, CD20-positivo difuso grande B grande linfoma de células B (DLBCL), linfoma de Burkitt (BL), linfoma tipo Burkitt (BLL) ou leucemia aguda de células B maduras (B-AL).
[/fusion_content_box][fusion_content_box title=”Pafolacianina (Cytalux, On Target Laboratories, LLC)” backgroundcolor=”” icon=”fa-arrow-alt-circle-right fas” iconflip=”” iconrotate=”” iconspin=”” iconcolor=”” circlecolor=”” circlebordersize=”” circlebordercolor=”” outercirclebordersize=”” outercirclebordercolor=”” image=”” image_id=”” image_max_width=”” link=”” linktext=”” link_target=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=””]
- Agente de imagem óptica. A pafolacianina é uma droga fluorescente que tem como alvo o receptor de folato que pode ser superexpresso no câncer de ovário. É usado com um sistema de imagem de fluorescência de infravermelho próximo (NIR) aprovado pelo FDA para uso específico com pafolacianina.
- Pacientes adultos com câncer de ovário como adjuvante na identificação interoperatória de lesões malignas.
[/fusion_content_box][/fusion_content_boxes][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]